Descripción del proyecto
Nuevo tratamiento farmacológico para el alcoholismo
El alcoholismo o trastorno por abuso del alcohol (TAA) es una importante fuente de preocupación en la Unión Europea y en todo el mundo. Habitualmente, el tratamiento implica un difícil proceso de desintoxicación que requiere apoyo físico y mental para ayudar al paciente a dejar el alcohol. Los tratamientos farmacológicos actuales no resultan óptimos y pueden causar efectos secundarios graves. El proyecto financiado con fondos europeos StopAddict está preparándose para revertir esta tendencia con la comercialización de un nuevo fármaco denominado KT-110. Desarrollado por la farmacéutica francesa Kinnov-Therapeutics, este nuevo fármaco, primero de su clase, permitirá a los pacientes controlar su consumo de alcohol. La eficacia de KT-110, tras veinte años de investigación y desarrollo preclínico, está relacionada con su acción sobre una vía recientemente descubierta, la cual tiene una gran implicación con la adicción al alcohol.
Objetivo
Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years. Alcoholism has also huge damaging effects on families, communities and the overall society. Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects. That situation leads to low patient recovery and only 10% of AUD people seeking for treatment.
In this context, Kinnov-Therapeutics has developed a new revolutionary first-in-class drug allowing patients to control their alcohol consumption. KT-110 drug will highly impact the European burden of AUD by decreasing alcohol consumption on AUD patients by 70% leading to triple the number of AUD people seeking for treatments and save more than 5 million lives per year and several billion of social cost expenses. The efficacy of KT-110 is related to its action on a newly discovered pathway highly implicated in alcohol addiction. This major understanding of AUD addiction mechanism was granted the European college of neuropsychopharmacology Neuropsychopharmacology Award in 2009.
After 20 years of intensive research and pre-clinical development, KT-110 has been accepted by the french regulatory agency for its first-in man phase II clinical trial by the end of 2018. This will be the main achievement of SMEi2 project. Moreover, all necessary actions for successful commercialisation to pharma companies (licensing deals) as well as continuous and updated IP and FTO issues are planned to be implemented during the SMEi2.
Through StopAddict project KT-110 will become the next leader of AUD treatments by generating €117m of cumulative revenues between 2025-2027. Our project will also allow to create more than 400 direct and indirect European jobs.
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-2
Régimen de financiación
SME - SME instrumentCoordinador
45100 Orleans
Francia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.